SCHOLAR ROCK HOLDING CORPORATION (SRRK) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Win.
26/58
2.2 / 5 stars
All 58 Win/Lose results and 62 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 5 wins, 3 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseSRRK / S&P 11.88% / 15.20% |
No dataSRRK / S&P / 15.00% |
LoseSRRK / S&P 13.70% / 50.40% |
| 2026-Q12/2 |
WinSRRK / S&P 11.60% / -4.33% |
No dataSRRK / S&P / 11.30% |
WinSRRK / S&P 36.22% / 27.70% |
| 2025-Q42/2 |
WinSRRK / S&P 18.29% / 2.65% |
No dataSRRK / S&P / 9.00% |
WinSRRK / S&P 34.15% / 13.40% |
| 2025-Q31/2 |
LoseSRRK / S&P 5.14% / 8.12% |
No dataSRRK / S&P / 4.61% |
WinSRRK / S&P 34.47% / 13.45% |
| 2025-Q21/2 |
LoseSRRK / S&P 10.17% / 10.94% |
No dataSRRK / S&P / 4.83% |
WinSRRK / S&P 31.53% / 10.63% |
| 2025-Q11/2 |
LoseSRRK / S&P -25.61% / -4.27% |
No dataSRRK / S&P / 4.98% |
WinSRRK / S&P 21.53% / 10.57% |
| 2024-Q42/2 |
WinSRRK / S&P 439.58% / 2.41% |
No dataSRRK / S&P / 5.25% |
WinSRRK / S&P 23.62% / 6.15% |
| 2024-Q31/2 |
LoseSRRK / S&P -3.84% / 5.89% |
No dataSRRK / S&P / 5.89% |
WinSRRK / S&P 20.51% / 6.11% |
| 2024-Q21/2 |
LoseSRRK / S&P -53.10% / 4.28% |
No dataSRRK / S&P / 5.38% |
WinSRRK / S&P 12.69% / 5.12% |
| 2024-Q10/2 |
LoseSRRK / S&P -5.53% / 10.56% |
No dataSRRK / S&P / 5.71% |
LoseSRRK / S&P -18.36% / 5.59% |
| 2023-Q41/2 |
WinSRRK / S&P 164.79% / 11.69% |
No dataSRRK / S&P / 6.81% |
LoseSRRK / S&P -12.72% / 7.78% |
| 2023-Q30/2 |
LoseSRRK / S&P -5.84% / -3.27% |
No dataSRRK / S&P / 7.52% |
LoseSRRK / S&P -30.11% / -5.03% |
| 2023-Q20/2 |
LoseSRRK / S&P -5.75% / 8.74% |
No dataSRRK / S&P / 9.50% |
LoseSRRK / S&P -39.57% / -8.57% |
| 2023-Q10/2 |
LoseSRRK / S&P -11.60% / 7.50% |
No dataSRRK / S&P / 10.77% |
LoseSRRK / S&P -15.79% / -15.69% |
| 2022-Q41/2 |
WinSRRK / S&P 30.59% / 7.56% |
No dataSRRK / S&P / 11.88% |
LoseSRRK / S&P -36.49% / -17.99% |
| 2022-Q31/2 |
WinSRRK / S&P 26.23% / -4.88% |
No dataSRRK / S&P / 13.47% |
LoseSRRK / S&P -18.18% / -1.41% |
| 2022-Q20/2 |
LoseSRRK / S&P -57.41% / -16.10% |
No dataSRRK / S&P / 13.71% |
LoseSRRK / S&P 2.52% / 11.04% |
| 2022-Q11/2 |
LoseSRRK / S&P -48.11% / -4.60% |
WinSRRK / S&P 213.65% / 15.97% |
No dataSRRK / S&P / 42.23% |
| 2021-Q41/2 |
LoseSRRK / S&P -24.77% / 11.03% |
WinSRRK / S&P 22.16% / 15.00% |
No dataSRRK / S&P / 96.40% |
| 2021-Q31/2 |
WinSRRK / S&P 14.26% / 0.58% |
LoseSRRK / S&P -6.84% / 10.77% |
No dataSRRK / S&P / 69.42% |
| 2021-Q20/2 |
LoseSRRK / S&P -42.95% / 8.55% |
LoseSRRK / S&P -25.85% / 6.58% |
No dataSRRK / S&P / 51.81% |
| 2021-Q10/2 |
LoseSRRK / S&P 4.39% / 6.17% |
LoseSRRK / S&P -32.72% / -1.06% |
No dataSRRK / S&P / 7.39% |
| 2020-Q41/2 |
WinSRRK / S&P 174.34% / 12.15% |
LoseSRRK / S&P -24.83% / -3.72% |
No dataSRRK / S&P / -33.42% |
| 2020-Q31/2 |
LoseSRRK / S&P -2.86% / 8.93% |
WinSRRK / S&P 51.25% / -2.04% |
No dataSRRK / S&P / -27.10% |
| 2020-Q22/2 |
WinSRRK / S&P 50.37% / 20.54% |
WinSRRK / S&P 161.23% / -0.46% |
No dataSRRK / S&P / -27.11% |
| 2020-Q12/2 |
WinSRRK / S&P -8.12% / -19.60% |
WinSRRK / S&P 621.70% / 3.47% |
No dataSRRK / S&P / -14.75% |
| 2019-Q41/1 |
WinSRRK / S&P 47.26% / 9.07% |
No dataSRRK / S&P / 5.36% |
No dataSRRK / S&P / 2.99% |
| 2019-Q30/1 |
LoseSRRK / S&P -43.57% / 1.70% |
No dataSRRK / S&P / 5.02% |
No dataSRRK / S&P / 0.21% |
| 2019-Q20/1 |
LoseSRRK / S&P -15.59% / 4.30% |
No dataSRRK / S&P / 6.64% |
No dataSRRK / S&P / 8.65% |
| 2019-Q10/1 |
LoseSRRK / S&P -18.20% / 13.65% |
No dataSRRK / S&P / 8.12% |
No dataSRRK / S&P / 14.29% |
| 2018-Q41/1 |
WinSRRK / S&P -10.80% / -13.52% |
No dataSRRK / S&P / 9.05% |
No dataSRRK / S&P / 18.23% |
| 2018-Q31/1 |
WinSRRK / S&P 65.06% / 7.71% |
No dataSRRK / S&P / 10.21% |
No dataSRRK / S&P / 19.06% |
| 2018-Q20/0 |
No dataSRRK / S&P / 3.43% |
No dataSRRK / S&P / 9.03% |
No dataSRRK / S&P / 14.46% |
| 2018-Q10/0 |
No dataSRRK / S&P / -0.76% |
No dataSRRK / S&P / 7.68% |
No dataSRRK / S&P / 12.46% |
| 2017-Q40/0 |
No dataSRRK / S&P / 6.64% |
No dataSRRK / S&P / 7.03% |
No dataSRRK / S&P / 13.82% |
| 2017-Q30/0 |
No dataSRRK / S&P / 4.48% |
No dataSRRK / S&P / 5.68% |
No dataSRRK / S&P / 17.57% |
| 2017-Q20/0 |
No dataSRRK / S&P / 3.09% |
No dataSRRK / S&P / 4.83% |
No dataSRRK / S&P / 17.74% |
| 2017-Q10/0 |
No dataSRRK / S&P / 6.07% |
No dataSRRK / S&P / 3.67% |
No dataSRRK / S&P / 13.32% |
| 2016-Q40/0 |
No dataSRRK / S&P / 3.82% |
No dataSRRK / S&P / 2.09% |
No dataSRRK / S&P / 7.05% |
| 2016-Q30/0 |
No dataSRRK / S&P / 3.85% |
No dataSRRK / S&P / 0.20% |
No dataSRRK / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SRRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 81.50% | 20.78% |
| Annualized return | 81.50% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SRRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 49.61% | 83.14% |
| Annualized return | 8.39% | 12.86% |
10Y · 2018-05-25 to 2026-08-27
| Metric | SRRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 295.07% | 319.30% |
| Annualized return | 14.73% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |